Chiho Ono

发表

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions

S. Yamazaki, C. Loi, Chiho Ono, 2017, Drug Metabolism and Disposition.

Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy

M. Ogura, K. Tobinai, T. Uchida, 2010, Cancer science.

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

T. Brümmendorf, G. Rosti, N. Takahashi, 2022, International Journal of Hematology.

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment

N. Takahashi, C. Nakaseko, K. Miyamura, 2017, International Journal of Hematology.

Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice

T. Izumi, Chiho Ono, R. Atsumi, 2009, Archives of Toxicology.

Absorption, distribution and excretion of 14C‐levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin‐related radioactivity to melanin in vivo

Chiho Ono, Makoto Tanaka, M. Yamada, 2003 .

Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo.

Chiho Ono, Makoto Tanaka, M. Yamada, 2003, The Journal of pharmacy and pharmacology.

Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies

T. Naoe, T. Miyamoto, M. Ikuta, 2017, Cancer science.

Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial

T. Brümmendorf, J. Cortes, C. Chuah, 2021, International Journal of Hematology.

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

T. Brümmendorf, G. Rosti, N. Takahashi, 2022, International Journal of Hematology.

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study

M. Hino, K. Ishizawa, I. Matsumura, 2022, International Journal of Hematology.

Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys.

Chiho Ono, R. Atsumi, A. Takao, 2004, Biological & pharmaceutical bulletin.

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study

M. Hino, K. Ishizawa, I. Matsumura, 2022, International Journal of Hematology.

New highly active taxoids from 9beta-dihydrobaccatin-9,10-acetals. Part 4.

T. Horiuchi, Y. Takeda, K. Uoto, 2003, Bioorganic & medicinal chemistry.

Absorption, distribution and excretion of 14C‐chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine‐related radioactivity to melanin in‐vivo

Chiho Ono, Makoto Tanaka, M. Yamada, 2003, The Journal of pharmacy and pharmacology.

Binding characteristics of fluoroquinolones to synthetic levodopa melanin

Chiho Ono, Makoto Tanaka, 2003, The Journal of pharmacy and pharmacology.

Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.

Misaki Suzuki, Ichiro Ieiri, Katsuomi Ichikawa, 2013, Pharmacogenomics.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

L. Tremaine, B. Feng, Y. Lai, 2012, Expert opinion on drug metabolism & toxicology.

Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia

M. Hino, C. Jung, T. Uchida, 2019, International Journal of Hematology.

Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

M. Ogura, K. Tobinai, K. Ando, 2012, Cancer science.

A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia

M. Taniwaki, N. Takahashi, K. Ishizawa, 2015, International Journal of Hematology.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

L. Tremaine, B. Feng, M. Varma, 2012, Expert opinion on drug metabolism & toxicology.

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

M. Ogura, K. Tobinai, T. Uchida, 2008 .